Evidence map›Paper›PMID 31432262›Full record

ArticleEuropean archives of psychiatry and clinical neuroscience2020

Is glutamate associated with fear extinction and cognitive behavior therapy outcome in OCD? A pilot study.

M Giménez, M Cano, I Martínez-Zalacaín, E Real, P Alonso, C Segalàs, J Munuera, L S Kegeles, J J Weinstein, X Xu and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of psychiatry and clinical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

M GiménezDepartment of Psychiatry, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2757-0145
M CanoDepartment of Psychiatry, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.ORCID http://orcid.org/0000-0003-0675-9483
I Martínez-ZalacaínDepartment of Psychiatry, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.ORCID http://orcid.org/0000-0002-4036-0284
E RealDepartment of Psychiatry, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.ORCID http://orcid.org/0000-0003-4523-1649
P AlonsoDepartment of Psychiatry, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5779-9111
C SegalàsDepartment of Psychiatry, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.ORCID http://orcid.org/0000-0002-0959-0356
J MunueraDiagnostic Imaging Department, Fundació de Recerca Hospital Sant Joan de Déu, Passeig Sant Joan de Déu, 2, Esplugues de Llobregat, 08950, Barcelona, Spain.ORCID http://orcid.org/0000-0001-5154-1796
L S KegelesDepartment of Psychiatry and Radiology, Columbia University, 622 W 168th St, New York, 10032, USA.ORCID http://orcid.org/0000-0002-8083-1167
J J WeinsteinDepartment of Psychiatry and Radiology, Columbia University, 622 W 168th St, New York, 10032, USA.
X XuDepartment of Psychiatry and Radiology, Columbia University, 622 W 168th St, New York, 10032, USA.ORCID http://orcid.org/0000-0002-3877-6483
J M MenchónDepartment of Psychiatry, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.ORCID http://orcid.org/0000-0002-6231-6524
N CardonerDepression and Anxiety Program, Department of Mental Health, Parc Taulí Sabadell, Hospital Universitari, Parc Taulí 1, 08208, Sabadell, Spain.ORCID http://orcid.org/0000-0001-9633-0888
C Soriano-MasDepartment of Psychiatry, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.ORCID http://orcid.org/0000-0003-4574-6597
M A FullanaCarlos III Health Institute, Centro de Investigación Biomédica en Red de Salud Mental-CIBERSAM, Av. de Monforte de Lemos 5, 28029, Madrid, Spain. mafullana@clinic.cat.ORCID http://orcid.org/0000-0003-3863-5223
Instituto de Salud Carlos III · ESNew York Psychoanalytic Society and Institute · USUniversitat Autònoma de Barcelona · ESBellvitge University Hospital · ESHospital Sant Joan de Déu Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cognitive behavioral therapy (CBT) including exposure and response prevention is a well-established treatment for obsessive-compulsive disorder (OCD) and is based on the principles of fear extinction. Fear extinction is linked to structural and functional variability in the ventromedial prefrontal cortex (vmPFC) and has been consistently associated with glutamate neurotransmission. The relationship between vmPFC glutamate and fear extinction and its effects on CBT outcome have not yet been explored in adults with OCD. We assessed glutamate levels in the vmPFC using 3T magnetic resonance spectroscopy, and fear extinction (learning and recall) using skin conductance responses during a 2-day experimental paradigm in OCD patients (n = 17) and in healthy controls (HC; n = 13). Obsessive-compulsive patients (n = 12) then received manualized CBT. Glutamate in the vmPFC was negatively associated with fear extinction recall and positively associated with CBT outcome (with higher glutamate levels predicting a better outcome) in OCD patients. Glutamate levels in the vmPFC in OCD patients were not significantly different from those in HC, and were not associated with OCD severity. Our results suggest that glutamate in the vmPFC is associated with fear extinction recall and CBT outcome in adult OCD patients.

Indexed as

Cognitive Behavioral TherapyObsessive-Compulsive DisorderOutcome Assessment, Health CareAdultExtinction, PsychologicalFearFemaleGalvanic Skin ResponseGlutamic AcidHumansMagnetic Resonance SpectroscopyMaleMiddle AgedPilot ProjectsPrefrontal CortexSeverity of Illness IndexGlutamic AcidCognitive behavioral therapy (CBT)Fear extinctionGlutamateObsessive–compulsive disorder (OCD)Ventromedial prefrontal cortex (vmPFC)

Identifiers

PMID31432262
OpenAlexW2969235659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.